Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia

References

• Wei G, Wang J, Huang H, et al. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia. J Hematol Oncol. 2017;10:150.
   PubMed Web of Science ®Google Scholar
• Blum S, Martins F, Lübbert M. Immunotherapy in adult acute leukemia. Leuk Res. 2017;60:63–73.
   PubMed Web of Science ®Google Scholar
• Huguet F, Tavitian S. Emerging biological therapies to treat acute lymphoblastic leukemia. Expert Opin Emerg Drugs. 2017;22:107–121.
   PubMed Web of Science ®Google Scholar
• Papadantonakis N, Advani AS. Recent advances and novel treatment paradigms in acute lymphocytic leukemia. Ther Adv Hematol. 2016;7:252–269.
   PubMed Web of Science ®Google Scholar
• Ok CY, Young KH. Checkpoint inhibitors in hematological malignancies. J Hematol Oncol. 2017;10:103.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740–753.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Ravandi F, Kebriaei P, et al. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial. JAMA Oncol. 2017. DOI:10.1021/jamaoncol.2017.2380
   PubMedGoogle Scholar
• Aldoss I, Bargou RC, Nagorsen D, et al. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors. Leukemia. 2017;31:777–787.
   PubMed Web of Science ®Google Scholar
• Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29:2493–2498.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gökbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32:4134–4140.
   PubMed Web of Science ®Google Scholar
• Von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34:4381–4389.
   PubMed Web of Science ®Google Scholar
• Nägele V, Kratzer A, Zugmaier G, et al. Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL. Exp Hematol Oncol. 2017;6:14.
   PubMedGoogle Scholar
• Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836–847.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Stein AS, Bargou RC, et al. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: results from 2 phase 2 studies. Cancer. 2016;122:2178–2185.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Kelsh M, Chia V, et al. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J. 2016;6:e473.
   PubMed Web of Science ®Google Scholar
• Zugmaier G, Gökbuget N, Klinger M, et al. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood. 2015;126(24):2578–2584.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57–66.
   PubMed Web of Science ®Google Scholar
• Barlev A, Lin VW, Katz A, et al. Estimating long-term survival of adults with philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia treated with blinatumomab using historical data. Adv Ther. 2017;34:148–155.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Boissel N, Chevallier P, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 2017;35:1795–1802.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gökbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120:5185–5187.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Zugmaier G, Klinger M, et al. Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia. Haematologica. 2017;102:e132–e135.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Dombret H, Bonifacio M, et al. BLAST: a confirmatory, single-arm, phase 2 study of blinatumomab, a bispecific T-cell engager (BiTE®) antibody construct, in patients with minimal residual disease b-precursor acute lymphoblastic leukemia (ALL). Blood. 2014;124:379(abstract).
   PubMed Web of Science ®Google Scholar
• Aldoss I, Song J, Stiller T, et al. Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2017 Sep;92:858–865. DOI:10.1002/ajh.24783
   PubMed Web of Science ®Google Scholar
• Ruella M, Maus MV. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput Struct Biotechnol J. 2016;14:357–362.
   PubMed Web of Science ®Google Scholar
• Sotillo E, Barrett DM, Black KL, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1282–1295.
   PubMed Web of Science ®Google Scholar
• Braig F, Brandt A, Goebeler M, et al. Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood. 2017;129:100–104.
   PubMed Web of Science ®Google Scholar
• Nagel I, Bartels M, Duell J, et al. Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as potential mechanism of resistance to blinatumomab therapy. Blood. 2017. DOI:10.1182/blood-2017-05-782888
   PubMed Web of Science ®Google Scholar
• Rayes A, McMasters RL, O’Brien MM. Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy. Pediatr Blood Cancer. 2016;63:1113–1115.
   PubMed Web of Science ®Google Scholar
• Duell J, Dittrich M, Bedke T, et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia. 2017;31:2181–2190.
   Web of Science ®Google Scholar
• Sidaway P. Haematological cancer: T(reg) predict responsiveness to blinatumomab. Nat Rev Clin Oncol. 2017;14:262.
   Google Scholar
• Kohnke T, Krupka C, Tischer J, et al. Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab. J Hematol Oncol. 2015;8:111.
   PubMed Web of Science ®Google Scholar
• Feucht J, Kayser S, Gorodezki D, et al. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget. 2016;7:76902–76919.
   PubMed Web of Science ®Google Scholar
• Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121:5154–5157.
   PubMed Web of Science ®Google Scholar
• Wilke AC, Gökbuget N. Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab. Expert Opin Drug Saf. 2017;1–12. DOI:10.1080/14740338.2017.1338270
   Web of Science ®Google Scholar
• Benjamin JE, Stein AS. The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia. Ther Adv Hematol. 2016;7:142–156.
   PubMed Web of Science ®Google Scholar
• Lee KJ, Chow V, Weissman A, et al. Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults. Ther Clin Risk Manag. 2016;12:1301–1310.
   PubMed Web of Science ®Google Scholar
• Franca R, Favretto D, Granzotto M, et al. Epratuzumab and blinatumomab as therapeutic antibodies for treatment of pediatric acute lymphoblastic leukemia: current status and future perspectives. Curr Med Chem. 2017;24:1050–1065.
   PubMed Web of Science ®Google Scholar
• Friberg G, Reese D. Blinatumomab (Blincyto): lessons learned from the bispecific T-cell engager (BiTE) in acute lymphocytic leukemia (ALL). Ann Oncol. 2017;28:2009–2012.
   PubMed Web of Science ®Google Scholar
• Zugmaier G, Topp MS, Alekar S, et al. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J. 2014;4:244.
   PubMed Web of Science ®Google Scholar
• Queudeville M, Handgretinger R, Ebinger M. Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia - role of blinatumomab. Onco Targets Ther. 2017;10:3567–3578.
   PubMed Web of Science ®Google Scholar
• Valecha GK, Ibrahim U, Ghanem S, et al. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia. Expert Rev Hematol. 2017;10:783–799.
   PubMed Web of Science ®Google Scholar
• Yuraszeck T, Kasichayanula S, Benjamin JE. Translation and clinical development of bispecific T-cell engaging antibodies for cancer treatment. Clin Pharmacol Ther. 2017;101:634–645.
   PubMed Web of Science ®Google Scholar
• Thomas X, Le Jeune C. Treating adults with acute lymphocytic leukemia: new pharmacotherapy options. Expert Opin Pharmacother. 2016;17:2319–2330.
   PubMed Web of Science ®Google Scholar
• Ueda M, De Lima M, Caimi P, et al. Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant. Bone Marrow Transplant. 2016;51:1253–1255.
   PubMed Web of Science ®Google Scholar
• Assi R, Kantarjian H, Short NJ, et al. Safety and efficacy of blinatumomab in combination with a thyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive ALL. Clin Lymphoma Myeloma Leukemia. 2017;17(suppl 2):S265 (abstract).
   PubMedGoogle Scholar
• Yilmaz M, Kantarjian H, Jabbour E. Treatment of acute lymphoblastic leukemia in older adults: now and the future. Clin Adv Hematol Oncol. 2017;15:266–274.
   PubMed Web of Science ®Google Scholar
• [cited 2017 Sep 14]. Available from: https://clinicaltrials.gov/
   Google Scholar
• Saini L, Brandwein J. New treatment strategies for philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2017;12:136–142.
   PubMed Web of Science ®Google Scholar
• Ruella M, Barrett DM, Kenderian SS, et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016;126:3814–3826.
   PubMed Web of Science ®Google Scholar